Abnormal Circulating Hepatic Transaminase Concentration C5936882
Elevated liver transaminases indicate liver cell injury, commonly detected on blood tests. Causes range from medications and alcohol to infections and metabolic conditions. Addressing the root cause typically helps enzyme levels return to normal.
Key facts at a glance
- ICD-10
- K76.9
- ICD-11
- DA00.0
- Body system
- hepatobiliary
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Confusion
Mental confusion, difficulty concentrating, or altered mental status due to hepatic encephalopathy.
IMMEDIATE medical attention required. Confusion or altered mental status is a medical emergency.
Fatigue
(constitutional)Persistent tiredness and lack of energy that is not relieved by rest.
Frequency: 60-70% of patients
Abdominal pain
(gastrointestinal)Discomfort or pain in the upper right abdomen where the liver is located.
Frequency: 40-50% of patients
Nausea
(gastrointestinal)Feeling of sickness with an urge to vomit.
Frequency: 30-40% of patients
Loss of appetite
(gastrointestinal)Reduced desire to eat or feeling full quickly after eating only small amounts.
Frequency: 30-40% of patients
Jaundice
(dermatologic)Yellowing of the skin and whites of the eyes due to elevated bilirubin.
Frequency: 20-30% of patients
Itching
(dermatologic)Generalized pruritus or itching without a visible skin rash.
Frequency: 10-15% of patients
Dark urine
(genitourinary)Urine that appears darker than usual, ranging from amber to brownish color.
Frequency: 10-15% of patients
Easy bruising
(dermatologic)Bruises appearing more easily or taking longer to heal due to impaired clotting factor production.
Frequency: 5-10% of patients
Leg swelling
(cardiovascular)Fluid accumulation in the lower legs causing swelling and puffiness.
Frequency: 5% of patients
Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Alcohol cessation and reduction
Complete elimination or significant reduction of alcohol consumption is essential for reducing transaminase elevation. Alcohol causes direct hepatotoxicity and increases oxidative stress on liver cells.
Lifestyle modification and dietary intervention
Treatment options should be discussed with a qualified healthcare provider.
Weight management and physical activity
Structured weight reduction through calorie control and regular exercise improves insulin sensitivity and reduces hepatic fat accumulation. Even modest weight loss of 5-10% can significantly improve liver enzyme levels.
Additional treatment options
Mediterranean-style diet
Anti-inflammatory dietary pattern emphasizing fruits, vegetables, whole grains, and healthy fats such as olive oil. This diet supports liver function and reduces hepatic inflammation.
dietaryHepatoprotective agents
Pharmaceutical hepatoprotectants may be prescribed to support liver cell regeneration and reduce oxidative damage. Choice depends on underlying etiology of transaminase elevation.
medicationSerial liver enzyme surveillance
Regular monitoring of ALT, AST, and related liver function tests to track disease progression or treatment response. Imaging may be indicated if underlying liver disease is suspected.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Abnormal Circulating Hepatic Transaminase Concentration C5936882?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
American Association for the Study of Liver Diseases. AASLD Practice Guideline: Evaluation of Abnormal Liver Tests. Hepatology. 2017.
Kwo PY, Cohen SM, Lim JK. Evaluation of Elevated Liver Tests. Clinical Gastroenterology and Hepatology. 2017;15(7):955-964.
American Gastroenterological Association. AGA Clinical Practice Update: Interpretation of Liver Chemistry Tests. Gastroenterology. 2020;159(4):1465-1476.
Lala V, Goyal A, Bansal P, Minter DA. Liver Function Tests. StatPearls. 2023.
Kim HC, Nam CM, Jee SH, et al. Normal Serum Aminotransferase Concentration and Risk of Cardiovascular Disease: A Prospective Cohort Study. Journal of Hepatology. 2008;48(1):169-176.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of Alcoholic Liver Disease. Journal of Hepatology. 2018;69(1):154-181.
Green RM, Flamm S. AGA Technical Review on the Evaluation of Liver Chemistry Tests. Gastroenterology. 2002;123(4):1367-1384.
World Health Organization. WHO Guidelines on Hepatitis B and C Testing. Geneva: WHO. 2017.
Medication Comparisons
Compare medications used to treat Abnormal Circulating Hepatic Transaminase Concentration C5936882. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy